{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-278804","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.192618+00:00","generated_at":"2026-05-16T20:11:44.119196+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aldeyra expands RASP platform to CNS diseases; reproxalap manufacturing inspections closed","bullets":["ADX-248 preclinical results in Parkinson's & ALS models showed improved grip strength, balance, and CNS biomarkers.","FDA completed reproxalap drug substance and product facility inspections; closed with VAI designation, no further action.","Aldeyra expanded RASP platform to central nervous system diseases; ADX-248 is oral next-gen RASP modulator.","Reproxalap is a first-in-class investigational candidate for dry eye disease signs and symptoms."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-278804","json":"https://secwatch.observer/filing/0001193125-25-278804.json","markdown":"https://secwatch.observer/filing/0001193125-25-278804.md","text":"https://secwatch.observer/filing/0001193125-25-278804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/0001193125-25-278804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/aldx-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:11:44.119196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}